Is Thrombolytic Therapy Associated With Increased Mortality?
Authors:
- Ahmet ErginAEAhmet Ergin
- Nesrin ErginNENesrin Ergin
Open Access
- 1 March 2005
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 62 (3) , 362-366
Abstract
Background Although thrombolytic therapy has shown substantial benefits in neural outcomes, concerns remain regarding the association between thrombolytic therapy and possible increased mortality. Objective To determine the mortality risk of certain thrombolytic agents that are a treatment option for acute ischemic stroke. Data Sources, Extraction, and Synthesis Studies were identified using MEDLINE, the Cochrane Central Register of Controlled Trials, and the reference lists of the articles selected. Randomized placebo-controlled trials of thrombolytic agents for the treatment of acute ischemic stroke patients were eligible. Study quality was evaluated using a previously validated scale. Data were extracted in duplicate by two independent investigators. All-cause mortality during follow-up was the main outcome. Random effects models were used to pool the individual effects of trials. Several preplanned sensitivity and subgroup analyses were completed to explain the heterogeneity among trials. Odds ratios, absolute risk differences, and numbers needed to harm were calculated. Results Eleven placebo-controlled randomized trials of thrombolytic agents involving 3709 participants were included in the analysis. Thrombolytic therapy was associated with an insignificant increase in mortality (odds ratio, 1.07; 95% confidence interval, 0.8-1.39; P = .3). The treatment was associated with an absolute increased risk of mortality of 11 per 1000 persons (95% confidence interval, −24 to 48; P = .3), and the number needed to harm was 84 (the 95% confidence interval included 0). Conclusion These findings suggest that thrombolytic therapy does not significantly increase all-cause mortality.Keywords
This publication has 8 references indexed in Scilit:
- Confidence intervals for the number needed to treatBMJ, 1998
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- Early Intravenous Thrombolysis for Acute Ischemic Stroke in a Community-Based ApproachStroke, 1998
- Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)JAMA, 1995
- Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.Stroke, 1993
- Ancrod Causes Rapid Thrombolysis in Patients with Acute StrokeThe American Journal of the Medical Sciences, 1990
- Use of ancrod in acute or progressing ischemic cerebral infarctionAnnals of Emergency Medicine, 1988
- A method for assessing the quality of a randomized control trialControlled Clinical Trials, 1981